Ligand ID: RBT


Drugbank ID:
DB00615
(Rifabutin)


Indication:
For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.

Get human targets for RBT in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'RBT' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A  20
GLU A 178
PHE A 103
VAL A 114
ILE A 136
1.64A19.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A  42
GLU A 178
PHE A 103
VAL A 114
ILE A 136
1.58A19.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6m0j SPIKE RECEPTOR
BINDING DOMAIN
(SARS-CoV-2)		4 / 7
ASN E 460
LEU E 461
ARG E 454
GLY E 416
1.39A19.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A  20
GLU A 178
PHE A 103
VAL A 114
ILE A 136
1.67A19.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
VAL A  42
GLU A 178
PHE A 103
VAL A 114
ILE A 136
1.57A19.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ARG C   4
LEU C 282
GLY A 170
SER C   1
1.49A19.37

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_M_RBTM8002_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
GLN A 299
ASP A 295
ARG A 298
SER C 123
ASN A 151
1.53A15.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_M_RBTM8002_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
GLN D 299
ASP D 295
ARG D 298
SER B 123
ASN D 151
1.70A15.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_C_RBTC8001_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN
RNA POLYMERASE SIGMA
FACTOR RPOD)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
GLN C 107
GLN C 110
PHE C 112
ASP C 295
ILE C 249
1.67A15.45
22.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
ARG A 298
GLY C 143
TYR C 118
SER C 144
1.75A19.37

None
3WL  C 401 (-3.4A)
None
3WL  C 401 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
LEU C 282
ARG C   4
GLY A 170
SER C   1
1.65A19.37

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_M_RBTM8002_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
GLN C 299
ASP C 295
ARG C 298
SER A 123
ASN C 151
1.65A15.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_M_RBTM8002_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
GLN B 299
ASP B 295
ARG B 298
SER D 123
ASN B 151
1.54A15.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6m71 NSP12
(SARS-CoV-2)		5 / 12
VAL A 354
GLU A 370
PHE A 506
PRO A 328
ILE A 539
1.75A19.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6m71 NSP12
(SARS-CoV-2)		5 / 12
VAL A 742
PRO A 243
VAL A 785
PHE A 745
PHE A 471
1.69A19.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 7
LEU A 514
ARG A 513
GLY A 503
SER A 501
1.74A9.82

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PRO C1053
PHE C1052
VAL C 785
PHE C 797
ILE C 788
1.52A18.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_C_RBTC8001_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN
RNA POLYMERASE SIGMA
FACTOR RPOD)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ARG A 765
GLN C1011
GLN C 954
PRO C 728
ILE C1018
1.55A22.25
15.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
LEU B 223
ARG B  34
GLY B 268
TYR B  91
1.32A7.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_M_RBTM8002_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ARG A 765
GLN C1011
GLN C 954
PRO C 728
ILE C1018
1.69A22.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ASN A  37
LEU A  43
GLY A  85
SER A  84
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ASN B  37
LEU B  43
GLY B  85
SER B  84
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PRO B1053
PHE B1052
VAL B 785
PHE B 797
ILE B 788
1.59A19.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ASN B 450
ARG B 346
ARG B 509
GLY B 496
1.43A6.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_M_RBTM8002_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ARG C 765
GLN B1011
GLN B 954
PRO B 728
ILE B1018
1.66A22.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_C_RBTC8001_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN
RNA POLYMERASE SIGMA
FACTOR RPOD)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ARG C 765
GLN B1011
GLN B 954
PRO B 728
ILE B1018
1.59A22.11
14.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PRO C1053
PHE C1052
VAL C 785
PHE C 797
ILE C 788
1.60A18.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 7
ASN C 460
LEU C 461
ARG C 454
GLY C 416
1.40A19.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w4b NSP9
(SARS-CoV-2)		4 / 7
LEU A 113
ARG A 112
GLY A 105
SER A 106
1.38A19.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ASN A6975
LEU A7004
GLY A7019
TYR A6979
1.71A21.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ARG A 217
LEU A 220
GLY A 258
SER A 254
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ASN A  40
LEU A  43
GLY A  79
SER A  80
1.76A22.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w6y NSP3
(SARS-CoV-2)		4 / 7
LEU A 164
ARG A 141
GLY A 133
SER A 128
1.74A22.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ASN B  37
LEU B  43
GLY B  85
SER B  84
1.55A22.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ASN A  37
LEU A  43
GLY A  85
SER A  84
1.55A22.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w75 NSP16
(SARS-CoV-2)		4 / 7
ASN A6975
LEU A7004
GLY A7019
TYR A6979
1.78A21.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w75 NSP16
(SARS-CoV-2)		4 / 7
ASN C6853
LEU C7050
ARG C7053
SER C6964
1.51A21.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
ASN B 146
LEU B 150
GLY B  38
SER B  85
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
ASN A 146
LEU A 150
GLY A  38
SER A  85
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
VAL A 242
PRO A 129
PHE A 304
PHE A 241
ILE A 151
1.62A20.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		4 / 7
ARG A  99
LEU A  97
GLY A 104
SER A 105
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wcf NSP3
(SARS-CoV-2)		4 / 7
ASN A  40
LEU A  43
GLY A  79
SER A  80
1.80A
MES  A 201 (-3.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wcf NSP3
(SARS-CoV-2)		4 / 7
ASN A  37
LEU A  43
GLY A  85
SER A  84
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wen NSP3
(SARS-CoV-2)		4 / 7
LEU A 164
ARG A 141
GLY A 133
SER A 128
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wen NSP3
(SARS-CoV-2)		4 / 7
ASN A  40
LEU A  43
GLY A  79
SER A  80
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wen NSP3
(SARS-CoV-2)		4 / 7
ASN A  37
LEU A  43
GLY A  85
SER A  84
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wey NSP3
(SARS-CoV-2)		4 / 7
ASN A 241
LEU A 247
GLY A 289
SER A 288
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wey NSP3
(SARS-CoV-2)		4 / 7
ASN A 244
LEU A 247
GLY A 283
SER A 284
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
ARG A 319
GLY B 335
TYR B 333
SER B 318
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ASN A6975
LEU A7004
GLY A7019
TYR A6979
1.77A
FMT  A7108 (-3.4A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ASN C6853
LEU C7050
ARG C7053
SER C6964
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ASN C6975
LEU C7004
GLY C7019
TYR C6979
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wkq NSP16
(SARS-CoV-2)		4 / 7
LEU A7010
ARG A7014
GLY A7076
SER A6964
1.72A
None
FMT  A7107 ( 2.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wkq NSP16
(SARS-CoV-2)		4 / 7
ASN C6975
LEU C7004
GLY C7019
TYR C6979
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wkq NSP16
(SARS-CoV-2)		4 / 7
ASN C6853
LEU C7050
ARG C7053
SER C6964
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wkq NSP16
(SARS-CoV-2)		4 / 7
ASN A6975
LEU A7004
GLY A7019
TYR A6979
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ASN D  37
LEU D  43
GLY D  85
SER D  84
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ASN B  37
LEU B  43
GLY B  85
SER B  84
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ASN C  40
LEU C  43
GLY C  79
SER C  80
1.77A
APR  C 201 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ASN C  37
LEU C  43
GLY C  85
SER C  84
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ASN D  40
LEU D  43
GLY D  79
SER D  80
1.73A
APR  D 201 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ASN B  40
LEU B  43
GLY B  79
SER B  80
1.79A
APR  B 201 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ASN D  40
LEU D  43
GLY D  78
SER D  80
1.79A
APR  D 201 (-3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ASN A  40
LEU A  43
GLY A  79
SER A  80
1.80A
APR  A 201 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ASN A  37
LEU A  43
GLY A  85
SER A  84
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
ASN A6975
LEU A7004
GLY A7019
TYR A6979
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 7
ARG A 217
LEU A 220
GLY A 258
SER A 254
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
VAL A 242
PRO A 129
PHE A 304
PHE A 241
ILE A 151
1.61A20.21
None
PO4  A 504 (-3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6y2f REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
VAL A  42
GLU A 178
PHE A 103
VAL A 114
ILE A 136
1.56A19.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_M_RBTM8002_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
GLN A 107
GLN A 110
PHE A 112
ASP A 295
ILE A 249
1.53A15.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ARG A 217
LEU A 220
GLY A 258
SER A 254
1.52A19.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		4 / 7
LEU A  81
ARG A  48
GLY A  45
TYR A  46
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ASN E 460
LEU E 461
ARG E 454
GLY E 416
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ASN A 460
LEU A 461
ARG A 454
GLY A 416
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
VAL A 341
PRO L  65
PHE A 338
ILE B  30
PHE A 374
1.61A17.71
None
None
None
None
DMS  A 901 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
VAL E 341
PRO C  65
PHE E 338
ILE H  30
PHE E 374
1.56A17.71
None
None
None
None
DMS  E 901 (-4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ASN E 460
LEU E 461
ARG E 454
GLY E 416
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ASN E 422
ARG E 457
GLY E 416
TYR E 421
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ASN A 460
LEU A 461
ARG A 454
GLY A 416
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ASN E 460
LEU E 461
ARG E 454
GLY E 416
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN A  37
LEU A  43
GLY A  85
SER A  84
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN B  37
LEU B  43
GLY B  85
SER B  84
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN E  37
LEU E  43
GLY E  85
SER E  84
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN C  37
LEU C  43
GLY C  85
SER C  84
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN E  40
LEU E  43
GLY E  79
SER E  80
1.80A
EPE  E 202 (-4.1A)
None
EPE  E 203 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN C  40
LEU C  43
GLY C  79
SER C  80
1.78A
None
None
EPE  C 202 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN D  37
LEU D  43
GLY D  85
SER D  84
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN E  37
LEU E  43
GLY E  85
SER E  84
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN C  40
LEU C  43
GLY C  79
SER C  80
1.80A
APR  C 201 (-3.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN D  37
LEU D  43
GLY D  85
SER D  84
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN B  40
LEU B  43
GLY B  79
SER B  80
1.80A
APR  B 201 (-3.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN A  37
LEU A  43
GLY A  85
SER A  84
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN B  37
LEU B  43
GLY B  85
SER B  84
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN C  37
LEU C  43
GLY C  85
SER C  84
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN A  37
LEU A  43
GLY A  85
SER A  84
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN C  37
LEU C  43
GLY C  85
SER C  84
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN B  37
LEU B  43
GLY B  85
SER B  84
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN B  40
LEU B  43
GLY B  79
SER B  80
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ASN C  40
LEU C  43
GLY C  79
SER C  80
1.78A
MES  C 201 (-4.2A)
None
None
EDO  A 204 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2A68_M_RBTM8002_1
(DNA-DIRECTED RNA
POLYMERASE BETA
CHAIN)		7btf NSP12
(SARS-CoV-2)		5 / 11
GLN A 224
PHE A 192
ASP A 194
ARG A 197
SER A 229
1.76A21.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		7btf NSP12
(SARS-CoV-2)		5 / 12
VAL A 435
PRO A 412
PHE A 442
VAL A 844
PHE A 429
1.72A19.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 7
LEU A  19
ARG A  18
GLY A  13
SER A  15
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 7
LEU A 514
ARG A 513
GLY A 503
SER A 501
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
VAL A  42
GLU A 178
PHE A 103
VAL A 114
ILE A 136
1.57A19.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BEC_C_RBTC601_1
(SCAFFOLD PROTEIN D13)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
VAL A  20
GLU A 178
PHE A 103
VAL A 114
ILE A 136
1.66A19.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4CP3_B_RBTB1129_1
(B-CELL LYMPHOMA 6
PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
LEU A 514
ARG A 513
GLY A 503
SER A 501
1.76A
None
A  P  14 ( 4.0A)
None
U  T   9 ( 2.7A)